(Yicai Global) May 8 -- Shanghai Zhangjiang (Group) will construct a brand new cell industry park in the Zhangjiang Science City to focus on the full industry chain of cellular therapy.
The science park, which is in Pudong New Area in eastern Shanghai, is also expected to produce China's first self-developed new cellular therapy treatment, which will hit the market next year, it announced today, state Kankan News reported. The report provided no further information about the new treatment. The new science city will also lure hospitals to enter it to benefit from its research achievements.
The sci-tech complex is home to more than 50 cell therapy companies, statistics show. The cellular sector complex will gradually form a mature comprehensive industrial cellular therapy chain that includes storage, research and development, production, transport, treatment and equipment, Zhangjiang said, adding it aims to cluster 500 companies there to create a production value of CNY50 billion (USD7.4 billion) by 2030, per the report.
Cell therapy, in which living cells are injected, grafted or implanted into patients -- e.g. T cells able to fight cancer cells -- is currently the leading-edge research field of bioscience and has great value in treating tumors, cardiovascular and cerebrovascular and nervous system diseases and diabetes, repairing joints and in organ transplants.
Formed in 1992, Zhangjiang develops and runs sci-tech parks. It was previously called Shanghai Zhangjiang Hi-Tech Park Development but changed its name in 2001. The company's facilities encompass office and residential buildings, schools and shopping malls.
Editor: Ben Armour